Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[225Ac]hu11B6-IgG3R435H
- Development stage
- Preclinical
- Lead developer
- Diaprost
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[225Ac]hu11B6-IgG3R435H is a preclinical-stage targeted alpha-particle radioimmunotherapy (TAT) agent developed by DiaProst AB. It consists of a humanized monoclonal antibody, hu11B6, engineered into an IgG3 subclass with an R435H Fc mutation designed to enhance binding to the neonatal Fc receptor (FcRn) and optimize its pharmacokinetic profile. The antibody is conjugated via a DOTA chelator to the alpha-emitting radionuclide Actinium-225 (225Ac). It specifically targets human kallikrein 2 (hK2/KLK2), a serine protease that is highly and almost exclusively expressed in prostate tissue and prostate cancer cells, including those in castration-resistant and androgen receptor-addicted states. Upon binding and internalization, the alpha radiation delivers high-energy particles that induce lethal double-strand DNA breaks in the tumor cells while minimizing damage to surrounding healthy tissue.
- Other names
- Actinium-225-labeled hu11B6-IgG3R435HActinium225-labeled hu11B6-IgG3R435HActinium 225-labeled hu11B6-IgG3R435H225Ac-hu11B6-IgG3R435H
02
Targets
HK2 (Hexokinase Type II)
Beyond the preview
Go deeper on [225Ac]hu11B6-IgG3R435H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [225Ac]hu11B6-IgG3R435H.